Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep;5(4):934-45.
doi: 10.5812/numonthly.14087. Epub 2013 Sep 10.

Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction

Mohammad Sajjad Rahnama'i  1 , Gommert A Van Koeveringe  1 , Philip E Van Kerrebroeck  1
Affiliations
Review

Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction

Mohammad Sajjad Rahnama'i et al. Nephrourol Mon. 2013 Sep.

Abstract

In this paper, a general introduction is given, presenting the overactive bladder syndrome (OAB) and its impact on the quality of life and economical burden in patients affected. Moreover, the anatomy, physiology and histology of the lower urinary tract are discussed, followed by a brief overview on the possible role of prostaglandin (PG) and phosphodiesterase type 5 (PDE5) in the urinary bladder. The current literature on the role and distribution of PGE2 and its receptors in the urinary bladder is discussed. In both animal models and in human studies, high levels of signaling molecules such as PG and cGMP have been implicated, in decreased functional bladder capacity and micturition volume, as well as in increased voiding contraction amplitude. As a consequence, inhibition of prostanoid production, the use of prostanoid receptor antagonists, or PDE inhibitors might be a rational way to treat patients with detrusor overactivity. Similarly, prostanoid receptor agonists, or agents that stimulate their production, might have a function in treating bladder underactivity.

Keywords: Phosphodiesetrase Type 5; Prostaglandins; Urinary Bladder; Urinary Bladder, Overactive.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. A Schematic View of Bladder Anatomy
Figure 2.
Figure 2.. A Schematic View of the Cellular Structure in the Different Bladder Layers
Figure 3 .
Figure 3 .. A Schematic View of Bladder Neuronal Control
Figure 4.
Figure 4.. A Schematic View of the Prostaglandin System in the Bladder
See this image and copyright information in PMC

References

    1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. - PubMed
    1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4–20. doi: 10.1002/nau.20798. - DOI - PubMed
    1. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl):S580–90. - PubMed
    1. Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol. 2007;17(4):231–6. doi: 10.1097/MOU.0b013e32819ed7f9. - DOI - PubMed
    1. Komaroff AL, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. 1996;101(3):281–90. doi: 10.1016/S0002-9343(96)00174-X. - DOI - PubMed

LinkOut - more resources